OPEN CFDA 93.213 ↗ Competitive Grant Competitive ~100h typical effort
HEAL

Initiative Whole Joint Health Program

🏛 National Institutes of Health (HHS-NIH11)

✓ Free, no account · Source: Grants.gov · Last verified Jul 16, 2026

⏰ Deadline
Oct 7, 2026 in 82 days
📅 Fiscal Year
FY 2027
📍 Scope
National

Can you apply?

This grant is for research institutions seeking to conduct mechanistic clinical research on joint pain. Applicants must be U.S. organizations capable of conducting phased clinical research with NIH standards for rigor and reproducibility. The program supports Phase 1 mechanism identification studies (2-3 years) and Phase 2 intervention testing (2-3 years), with a maximum project duration of 5 years. Projects must investigate whole joint biology, including periarticular tissues like muscle, adipose, ligaments, tendons, and fascia in relation to joint pain.

Eligible applicants
Check your eligibility — what type of organization are you?

Not the right fit? Find grants for your organization in 5 questions →

Key dates

  1. Feb 17, 2026 Applications open
  2. Oct 7, 2026 Application deadline in 82 days
  3. Jul 20, 2027 Award announced
  4. Jul 27, 2027 Project start

Program description

The National Center for Complementary and Integrative Health (NCCIH) plans to publish a Notice of Funding Opportunity (NOFO) that will support a phased mechanistic clinical research program focusing on understudied biological mechanisms that drive joint pain. The initiative responds to priorities identified in the 2023 HEAL Whole Joint Pain Workshop and supports the broader goals of the NIH Helping to End Addiction Long-term (HEAL) Initiative and the Make America Healthy Again vision by advancing safe, non-addictive, and prevention-oriented approaches to chronic pain.

Joint pain affects nearly half of adults in the United States. Many current treatments provide incomplete or temporary relief, informed by clinical trials that focus on joint structures such as bone or cartilage in isolation, without addressing contributions from additional tissues comprising the “whole joint”. New advances in imaging, biomechanics, tissue-specific omics, electrophysiology, and digital health tools now allow for a more complete evaluation of the whole joint, including periarticular tissues such as muscle, adipose, ligaments, tendons, and fascia.

The phased projects supported by this program will first identify and validate multi-tissue mechanisms underlying joint pain, then test non-pharmacological or multimodal interventions that directly target these mechanisms. Please note that while applications can specify the length of time for each of the following study phases, the total project length cannot exceed 5 years:

Phase 1 (2 to 3 years): Projects will identify multisystem mechanisms that include signals from periarticular tissues (e.g., muscles, adipose, and connective tissues including ligaments, tendons, or fascia) and their potential interactions with articular tissues (e.g., bone, synovium, cartilage) or the peripheral nervous system that contribute to joint pain and pathophysiology. Studies may incorporate imaging, biomarker profiling, neuromuscular assessment, behavioral or environmental factors, and other multimodal approaches that meet or exceed NIH standards for rigor and reproducibility.

Phase 2 (2 to 3 years): Successful phase 1 projects will receive additional funding to test the impact that non-pharmacological and/or multimodal interventions have on the identified multi-tissue mechanisms, to define how these interventions work to correct pathophysiology, aid healing, and resolve pain in the joint. Proposed interventions may include physical therapy, mind-body approaches, biomechanical strategies, or integrated multimodal treatments.

This phased approach is intended to accelerate the development of safe, accessible, non-addictive strategies that improve function, mobility, and quality of life for people with chronic joint pain. It will generate high-quality mechanistic evidence that supports whole joint and whole person models of care and contributes to nationwide efforts to reduce chronic pain and opioid dependence using non-pharmacological interventions and multimodal therapies.

Who can apply

Eligible applicants

How to apply

Application links

Key dates & requirements

  • Project period: 60 months
  • 📅 Expected award date: Jul 20, 2027
  • 🚀 Project start date: Jul 27, 2027

Required documents

  • NIH Standard Biosketch (current format)
  • Project Narrative and Specific Aims
  • Research Strategy (including preliminary data)
  • Budget and Budget Justification
  • Institutional biosafety or IRB approval documentation
  • Letters of support from collaborators

Program contact

Funding track record

Recent awards under CFDA 93.213 from the last 3 years — real organizations that won funding through this same program.

82
awards (3 yrs)
$577M
total funded
56
unique recipients
$7.0M
average award

Top 10 Largest Recent Awards

  1. $22,367,527
  2. $21,646,919
  3. $19,236,131
  4. $17,730,528
  5. $15,036,701
  6. $14,473,882
  7. $12,748,932
  8. $11,956,053
  9. $11,225,697
  10. $10,919,780

Top States by Funding

  • CA 13 awards $83.5M
  • MA 13 awards $80.2M
  • WA 8 awards $69.9M
  • NC 7 awards $53.8M
  • NY 6 awards $40.0M

Source: USAspending.gov — federal spending transparency. Data covers last 3 years.

Funding history

Annual funding for this program — Federal obligations (CFDA 93.213). How funding has trended year over year.

2024 $240,178,154
2025 $232,899,116
2026 est. $2,655,626

FAQ

Who can apply for this grant?

U.S.-based research institutions, universities, and other organizations capable of conducting rigorous clinical research are eligible. Applicants should have relevant expertise in joint biology or pain mechanisms.

What is the deadline?

The deadline is fixed for October 7, 2026. Check the NIH NCCIH website for exact application dates and any additional deadline windows.

What activities does this support?

Phase 1 funds mechanism identification studies using imaging, biomarkers, and multimodal approaches. Phase 2 tests non-pharmacological or multimodal interventions targeting identified mechanisms.

How competitive is this?

This is a competitive federal grant requiring strong preliminary data, rigorous study design, and evidence of team expertise. Alignment with NIH HEAL Initiative priorities strengthens applications.

What is the typical funding range?

The NOFO will specify the award range. Contact NIH NCCIH for current funding estimates or check the published NOFO for details.

💡 Tips for applicants

  • Emphasize whole joint approach: integrate data from multiple tissue types (muscle, bone, cartilage, fascia) rather than single-tissue mechanisms.
  • Design a realistic phased timeline: clearly differentiate Phase 1 mechanism work from Phase 2 intervention testing, staying within the 5-year maximum.
  • Demonstrate rigor: show compliance with NIH standards for reproducibility, including pre-registration, blinding, and sample size justification.
  • Highlight innovation in methods: leverage advances in imaging, omics, electrophysiology, or digital health tools to strengthen your mechanistic approach.
  • Connect to HEAL Initiative: explicitly link your project to reducing opioid use and advancing safe, non-addictive pain management strategies.

⚠️ Common mistakes

Focusing on single tissue structures (bone or cartilage alone) instead of whole joint and periarticular tissues. Proposing projects exceeding 5 years total duration or unclear phase transitions. Lacking sufficient preliminary data or mechanistic rationale for Phase 2 intervention selection.

Similar grants

Source: Grants.gov · FY 2027 · Last updated May 27, 2026

82 days left Oct 7, 2026
Apply →